Eli Lilly and Novo Nordisk are currently the only drugmakers with FDA approved weight-loss medicines on the U.S. market.

More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...

China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Novo Nordisk, Eli Lilly Tea Up Next-Gen Drugs. For Novo Nordisk stock, though, it will be important to see how the company builds its pipeline of experimental weight-loss drugs, says Carnegie's Afzal.

Novo Nordisk's weight loss candidate in question is called amycretin. The company is developing an oral and a subcutaneous version of this medicine. Amycretin is a GLP-1 agonist, ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO the door. Novo Nordisk announced Friday that Lars Fruergaard Jorgensen ...

What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli Lilly began marketing its rival product Mounjaro in the world's most ...